TC BioPharm Addresses Nasdaq Delisting Concerns
TC BioPharm (Holdings) PLC (NASDAQ: TCBP), known for developing groundbreaking allogeneic gamma-delta T cell therapies aimed at treating cancer, has moved to clear the air concerning misleading rumors about its status on the Nasdaq stock exchange. These fabrications, circulating on social media, claimed that the company was preparing to delist and relocate its trading to another platform.
Company Reassures Stakeholders
The company has categorically rejected the allegations that it was filing an 8-K Notice to delist, asserting that they are without merit. In an official statement, TC BioPharm affirmed its compliance with all Nasdaq listing criteria and expressed no intentions of seeking delisting. The firm holds a resolute stance against false reporting, emphasizing its commitment to transparency and integrity in the market.
Commitment to Transparency
In line with its dedication to uphold investor trust, TC BioPharm encourages any parties with questions or concerns to directly reach out to the company. Their message is clear: they are focused on maintaining open lines of communication and providing the public with accurate information regarding their operations and growth plans.
Innovative Therapies on the Horizon
TC BioPharm is recognized as a frontrunner in gamma-delta T cell treatment, currently advancing clinical trials that include a pivotal Phase 2b/3 trial targeting acute myeloid leukemia. They leverage cutting-edge technology known as CryoTC, designed for the delivery of frozen allogeneic cell products to healthcare facilities around the globe.
Significant Developments in Research
In other noteworthy updates, TC BioPharm has embarked on exciting preclinical studies for its new therapeutic candidate, TCB 008, focusing on the treatment of monkeypox. In collaboration with a prominent Infectious Disease Center or university, TC BioPharm aims to accelerate this research and contribute to addressing viral infections.
Advancements in Clinical Trials
The company is making headway in its ACHIEVE Phase 2b clinical trial, demonstrating progress in their innovative approaches to immunotherapy. Moreover, TC BioPharm has secured a European patent for its modified gamma-delta T cell therapies, which signal potential breakthroughs in treating various cancers and viral conditions.
Financial Stability and Market Activity
On the financial front, TC BioPharm recently raised approximately $2 million through a direct offering of shares and warrants, complemented by an additional $3.9 million from warrant exercises, facilitated by H.C. Wainwright & Co. as the exclusive placement agent. The company is also committed to complying with Nasdaq's Minimum Stockholders' Equity Requirement, ensuring its continued presence on the Nasdaq Global Select Market.
Market Challenges and Opportunities
Despite the positive developments, TC BioPharm is navigating a challenging financial landscape. Reports indicate their market capitalization is currently at about $1.09 million, pointing to the hurdles the company faces in a competitive biotechnology environment.
Investor Insights and Future Outlook
Investor data suggests that the company has been experiencing financial difficulties, including rapid cash depletion and potential challenges in meeting interest obligations on debts. These concerns are particularly pertinent as TC BioPharm is deeply invested in the costly process of developing new cancer therapies.
Navigating Stock Performance
Recent figures indicate a troubling 97.3% decline in the company's stock total return over the past year, a reflection of the broader issues at play in TC BioPharm's financial health, which includes an adjusted EBITDA of -$16.31 million. Nonetheless, TC BioPharm's ongoing trials and sustained Nasdaq listing embody its resilience and commitment to restoring investor confidence during these turbulent times.
Frequently Asked Questions
What did TC BioPharm say about the delisting rumors?
TC BioPharm firmly denied the rumors and confirmed that they remain compliant with Nasdaq listing requirements.
Is TC BioPharm still conducting clinical trials?
Yes, TC BioPharm is actively conducting clinical trials, including for acute myeloid leukemia and other cancer treatments.
What innovative technologies is TC BioPharm using?
The company utilizes CryoTC technology for delivering frozen allogeneic cell products to clinics worldwide.
How is TC BioPharm performing financially?
The company's market capitalization is around $1.09 million, indicating some financial challenges, but they have secured funding through share offerings.
What are TC BioPharm's future plans?
TC BioPharm plans to continue its clinical trials and also intends to acquire a biotechnology firm specializing in CAR T-cell therapies.
